In vitro efficacy of forodesine and nelarabine (ara-G) in pediatric leukemia

Blood

Volumn 118, Issue 8, 2011, Pages 2184-2190

  Homminga, Irene ^a   Zwaan, C Michel ^a   Manz, Chantal Y ^b   Parker, Cynthia ^c   Bantia, Shanta ^c   Smits, Willem Korstiaan ^a   Higginbotham, Fiona ^b   Pieters, Rob ^a   Meijerink, Jules P P ^a  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^b Mundipharma International Limited   (United Kingdom)

^c BIOCRYST PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE; CARRIER PROTEIN; DAUNORUBICIN; FORODESINE; GUANOSINE TRIPHOSPHATE; MESSENGER RNA; NELARABINE; NUCLEOSIDE; PREDNISONE; PROTEIN ENT1; PROTEIN ENT2; UNCLASSIFIED DRUG; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; B CELL PRECURSOR ACUTE MYELOID LEUKEMIA; CHILDHOOD CANCER; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG EFFICACY; DRUG POTENTIATION; DRUG SENSITIVITY; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA; MAJOR CLINICAL STUDY; PRE B LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PURINE METABOLISM;

EID: 80052158260     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-02-337840     Document Type: Article

References (44)

1. Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med. 2006;354(2):166-178.
2. Kaspers GJ, Zwaan CM. Pediatric acute myeloid leukemia: towards high-quality cure of all patients. Haematologica. 2007;92(11):1519-1532.
3. Bassan R, Hoelzer D. Modern therapy of acute lymphoblastic leukemia. J Clin Oncol. 2011;29(5):532-543.
4. Burnett A, Wetzler M, Lowenberg B. Therapeutic advances in acute myeloid leukemia. J Clin Oncol. 2011;29(5):487-494.
5. Miles RW, Tyler PC, Furneaux RH, Bagdassarian CK, Schramm VL. One-third-the-sites transitionstate inhibitors for purine nucleoside phosphorylase. Biochemistry. 1998;37(24):8615-8621.
6. Alonso R, Lopez-Guerra M, Upshaw R, et al. Forodesine has high antitumor activity in chronic lymphocytic leukemia and activates p53-independent mitochondrial apoptosis by induction of p73 and BIM. Blood. 2009;114(8):1563- 1575.
7. Bantia S, Ananth SL, Parker CD, Horn LL, Upshaw R. Mechanism of inhibition of T-acute lymphoblastic leukemia cells by PNP inhibitor-BCX-1777. Int Immunopharmacol. 2003;3(6):879-887.
8. Kicska GA, Long L, Horig H, et al. Immucillin H, a powerful transition-state analog inhibitor of purine nucleoside phosphorylase, selectively inhibits human T lymphocytes. Proc Natl Acad Sci U S A. 2001;98(8):4593-4598.
9. Balakrishnan K, Nimmanapalli R, Ravandi F, Keating MJ, Gandhi V. Forodesine, an inhibitor of purine nucleoside phosphorylase, induces apoptosis in chronic lymphocytic leukemia cells. Blood. 2006;108(7):2392-2398.
10. Carson DA, Kaye J, Matsumoto S, Seegmiller JE, Thompson L. Biochemical basis for the enhanced toxicity of deoxyribonucleosides toward malignant human T cell lines. Proc Natl Acad Sci U S A. 1979;76(5):2430-2433.
11. Carson DA, Kaye J, Seegmiller JE. Lymphospecific toxicity in adenosine deaminase deficiency and purine nucleoside phosphorylase deficiency: possible role of nucleoside kinase(s). Proc Natl Acad Sci U S A. 1977;74(12):5677-5681.
12. Cohen A, Gudas LJ, Ammann AJ, Staal GE, Martin DW Jr. Deoxyguanosine triphosphate as a possible toxic metabolite in the immunodeficiency associated with purine nucleoside phosphorylase deficiency. J Clin Invest. 1978;61(5):1405-1409.
13. Giblett ER, Ammann AJ, Wara DW, Sandman R, Diamond LK. Nucleoside-phosphorylase deficiency in a child with severely defective T-cell immunity and normal B-cell immunity. Lancet. 1975;1(7914):1010-1013.
14. Cohen A, Lee JW, Gelfand EW. Selective toxicity of deoxyguanosine and arabinosyl guanine for T-leukemic cells. Blood. 1983;61(4):660-666.
15. Verhoef V, Fridland A. Metabolic basis of arabinonucleoside selectivity for human leukemic T- and B-lymphoblasts. Cancer Res. 1985;45(8):3646-3650.
16. Shewach DS, Daddona PE, Ashcraft E, Mitchell BS. Metabolism and selective cytotoxicity of 9-beta-D-arabinofuranosylguanine in human lymphoblasts. Cancer Res. 1985;45(3):1008-1014.
17. Ullman B, Martin DW Jr. Specific cytotoxicity of arabinosylguanine toward cultured T lymphoblasts. J Clin Invest. 1984;74(3):951-955.
18. Lambe CU, Averett DR, Paff MT, Reardon JE, Wilson JG, Krenitsky TA. 2-amino-6-methoxypurine arabinoside: an agent for T-cell malignancies. Cancer Res. 1995;55(15):3352-3356.
19. Gandhi V, Kilpatrick JM, Plunkett W, et al. A proof-of- principle pharmacokinetic, pharmacodynamic, and clinical study with purine nucleoside phosphorylase inhibitor immucillin-H (BCX-1777, forodesine). Blood. 2005;106(13):4253-4260.
20. Balakrishnan K, Verma D, O'Brien S, et al. Phase 2 and pharmacodynamic study of oral forodesine in patients with advanced, fludarabine-treated chronic lymphocytic leukemia. Blood. 2010;116(6):886-892.
21. Al-Kali A, Gandhi V, Ayoubi M, Keating M, Ravandi F. Forodesine: review of preclinical and clinical data. Future Oncol. 2010;6(8):1211-1217.
22. DeAngelo DJ, Yu D, Johnson JL, et al. Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801. Blood. 2007;109(12):5136-5142.
23. Berg SL, Blaney SM, Devidas M, et al. Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children's Oncology Group. J Clin Oncol. 2005;23(15):3376-3382.
24. Kurtzberg J, Ernst TJ, Keating MJ, et al. Phase I study of 506U78 administered on a consecutive 5-day schedule in children and adults with refractory hematologic malignancies. J Clin Oncol. 2005;23(15):3396-3403.
25. Stam RW, den Boer ML, Meijerink JP, et al. Differential mRNA expression of Ara-C-metabolizing enzymes explains Ara-C sensitivity in MLL generearranged infant acute lymphoblastic leukemia. Blood. 2003;101(4):1270-1276.
26. Den Boer ML, Harms DO, Pieters R, et al. Patient stratification based on prednisolone-vincristine-asparaginase resistance profiles in children with acute lymphoblastic leukemia. J Clin Oncol. 2003;21(17):3262-3268.
27. Sherman PA, Fyfe JA. Enzymatic assay for deoxyribonucleoside triphosphates using synthetic oligonucleotides as template primers. Anal Biochem. 1989;180(2):222-226.
28. Meijerink J, Mandigers C, van de Locht L, Tonnissen E, Goodsaid F, Raemaekers J. A novel method to compensate for different amplification efficiencies between patient DNA samples in quantitative real-time PCR. J Mol Diagn. 2001;3(2):55-61.
29. Hubeek I, Stam RW, Peters GJ, et al. The human equilibrative nucleoside transporter 1 mediates in vitro cytarabine sensitivity in childhood acute myeloid leukaemia. Br J Cancer. 2005;93(12):1388-1394.
30. Zwaan CM, Kaspers GJ, Pieters R, et al. Different drug sensitivity profiles of acute myeloid and lymphoblastic leukemia and normal peripheral blood mononuclear cells in children with and without Down syndrome. Blood. 2002;99(1):245-251.
31. Zwaan MC, Reinhardt D, Hitzler J, Vyas P. Acute leukemias in children with Down syndrome. Pediatr Clin North Am. 2008;55(1):53-70, x.
32. Bantia S, Miller PJ, Parker CD, et al. Purine nucleoside phosphorylase inhibitor BCX-1777 (Immucillin-H)-a novel potent and orally active immunosuppressive agent. Int Immunopharmacol. 2001;1(6):1199-1210.
33. Shewach DS, Mitchell BS. Differential metabolism of 9-beta-D- arabinofuranosylguanine in human leukemic cells. Cancer Res. 1989;49(23): 6498-6502.
34. Pieters R, Huismans DR, Loonen AH, et al. Adenosine deaminase and purine nucleoside phosphorylase in childhood lymphoblastic leukemia: relation with differentiation stage, in vitro drug resistance and clinical prognosis. Leukemia. 1992;6(5):375-380.
35. Dumontet C, Fabianowska-Majewska K, Mantincic D, et al. Common resistance mechanisms to deoxynucleoside analogues in variants of the human erythroleukaemic line K562. Br J Haematol. 1999;106(1):78-85.
36. Kawasaki H, Shindou K, Higashigawa M, et al. Deoxycytidine kinase mRNA levels in leukemia cells with competitive polymerase chain reaction assay. Leuk Res. 1996;20(8):677-682.
37. Owens JK, Shewach DS, Ullman B, Mitchell BS. Resistance to 1-beta-D-arabinofuranosylcytosine in human T-lymphoblasts mediated by mutations within the deoxycytidine kinase gene. Cancer Res. 1992;52(9):2389-2393.
38. Stegmann AP, Honders MW, Kester MG, Landegent JE, Willemze R. Role of deoxycytidine kinase in an in vitro model for AraC- and DAC-resistance: substrate-enzyme interactions with deoxycytidine, 1-beta-D- arabinofuranosylcytosine and 5-aza-2′-deoxycytidine. Leukemia. 1993;7(7):1005-1011.
39. Kakihara T, Fukuda T, Tanaka A, et al. Expression of deoxycytidine kinase (dCK) gene in leukemic cells in childhood: decreased expression of dCK gene in relapsed leukemia. Leuk Lymphoma. 1998;31(3-4):405-409.
40. Stammler G, Zintl F, Sauerbrey A, Volm M. Deoxycytidine kinase mRNA expression in childhood acute lymphoblastic leukemia. Anticancer Drugs. 1997;8(5):517-521.
41. Rodriguez CO Jr, Mitchell BS, Ayres M, Eriksson S, Gandhi V. Arabinosylguanine is phosphorylated by both cytoplasmic deoxycytidine kinase and mitochondrial deoxyguanosine kinase. Cancer Res. 2002;62(11):3100-3105.
42. White JC, Rathmell JP, Capizzi RL. Membrane transport influences the rate of accumulation of cytosine arabinoside in human leukemia cells. J Clin Invest. 1987;79(2):380-387.
43. Huang M, Wang Y, Gu J, et al. Determinants of sensitivity of human T-cell leukemia CCRF-CEM cells to immucillin-H. Leuk Res. 2008;32(8):1268-1278.
44. Balakrishnan K, Burger JA, Quiroga MP, et al. Influence of bone marrow stromal microenvironment on forodesine-induced responses in CLL primary cells. Blood. 2010;116(7):1083-1091.